REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), dated as of April 23, 1999, is entered into by and among Generex Biotechnology Corp., an Idaho corporation, with headquarters located at 33 Harbour Square, Suite 202,...Registration Rights Agreement • July 12th, 1999 • Generex Biotechnology Corp • Pharmaceutical preparations • Illinois
WHEREAS, Modi has advised GPI that he intends to exercise his right to terminate the Consulting Agreement in the absence of agreements and procedures that will assure the continued involvement of Modi and the Management Group in the development of the...Agreement • December 14th, 1998 • Generex Biotechnology Corp • Ontario
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 25th, 2015 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 24, 2015, between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • November 12th, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
Exhibit 4.19 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of February 13, 2004, by and among Generex Biotechnology Corporation, a Delaware corporation (the "Company"), and the...Registration Rights Agreement • March 1st, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
AUGUST 6, 2003Stockholders' Agreement • October 29th, 2003 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 29th, 2017 • Generex Biotechnology Corp • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into on March 24, 2017 between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
I. ASSIGNMENT AND ASSUMPTION AGREEMENT THIS AGREEMENT made as of the 1st day of October, 1996 B E T W E E N: DR. PANKAJ MODI, an individual residing in the City of Hamilton, in the Province of Ontario, (hereinafter called the "Assignor")Assignment and Assumption Agreement • February 24th, 1999 • Generex Biotechnology Corp • Pharmaceutical preparations • Ontario
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 3rd, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 25, 2020, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the "Company"), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New York, NY 10022 (the "Buyer").
WITNESSETH:Employment Agreement • April 11th, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
EXHIBIT 4.3 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM...Generex Biotechnology Corp • July 14th, 2004 • Pharmaceutical preparations
EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • August 15th, 2003 • Generex Biotechnology Corp • Pharmaceutical preparations • Massachusetts
EXHIBIT 4.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of November 10, 2004, among Generex Biotechnology Corporation, a Delaware corporation (the "Company"), and the purchasers...Registration Rights Agreement • November 12th, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of January 7, 2000, is entered into by and among Generex Biotechnology Corp., a Delaware corporation, with headquarters located at 33 Harbour Square, Suite...Registration Rights Agreement • March 14th, 2000 • Generex Biotechnology Corp • Pharmaceutical preparations • Illinois
Exhibit 4.10 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of February 6, 2004, by and among Generex Biotechnology Corporation, a Delaware corporation (the "Company"), and the investors...Registration Rights Agreement • March 1st, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
EXHIBIT 4.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION...Generex Biotechnology Corp • November 12th, 2004 • Pharmaceutical preparations
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • July 14th, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT generex biotechnology corporationGenerex Biotechnology Corp • June 25th, 2015 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT To Purchase n Shares of Common Stock of GENEREX BIOTECHNOLOGY CORPORATIONGenerex Biotechnology Corp • October 16th, 2006 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, n (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the 181st day after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the fifth (5th) anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to n shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • March 1st, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 3rd, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of June 25, 2020, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the "Company"), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company (together with it permitted assigns, the "Buyer"). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").
BETWEENLicense Agreement • September 9th, 2003 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 16th, 2009 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated June 15, 2009, between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION...Generex Biotechnology Corp • November 12th, 2004 • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 6th, 2017 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March ___, 2017, between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENT (US) This REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of May ___, 2000, is entered into by and among Generex Biotechnology Corporation, a Delaware corporation, with headquarters located at 33 Harbour...Registration Rights Agreement • June 13th, 2000 • Generex Biotechnology Corp • Pharmaceutical preparations • Illinois
6% SECURED CONVERTIBLE DEBENTURE DUE MAY 28, 2007Generex Biotechnology Corp • October 16th, 2006 • Pharmaceutical preparations • New York
THIS DEBENTURE of Generex Biotechnology Company, a Delaware corporation, having a principal place of business at 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J2G2 (the “Company”), is designated as its 6% Convertible Debenture, due May 28, 2007 (the “Debenture”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 7th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of August 4, 2020, by and among Generex Biotechnology Corporation, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, Florida 33025 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • March 1st, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
WARRANTGenerex Biotechnology Corp • March 1st, 2004 • Pharmaceutical preparations
NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Common Stock Purchase Warrant • February 18th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • Nevada
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the $1,100,000.00 convertible promissory note to the Holder (as defined below) of even date) (the “Note”), Auctus Fund, LLC, a Delaware limited liability company (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to 62,857 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated August 14, 2019, by and among t
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 2nd, 2008 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 31, 2008, is by and among Generex Biotechnology Corporation, a Delaware corporation with headquarters located at 33 Harbour Square, Suite 202, Toronto, Ontario, Canada (the “Company”), and the undersigned buyers (each, a “Buyer”, and collectively, the “Buyers”).
COMMON STOCK PURCHASE WARRANT generex biotechnology corporationGenerex Biotechnology Corp • March 28th, 2014 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ANDDevelopment and License Agreement • January 24th, 2001 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT GENEREX BIOTECHNOLOGY CORPORATIONGenerex Biotechnology Corp • April 8th, 2010 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Midtown Partners & Co., LLC (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is 183 days after date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the effective date of the Registration Statement on Form S-3 to which this warrant relate in accordance with FINRA rule 5110(f)(2)(H)(i)(the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to n shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share;. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
